Recent studies suggest the potential role of other immune checkpoint or agonist proteins (i.e. LAG 3 or TIGIT and OX40, respectively) as MM therapeutic targets, alone and in combination with MM targeted and immune therapies (101). Here, TIGIT is linked to Miyoshi myopathy.